Metraipolis › archive › dc_04ed945176ef

Paclitaxel and carboplatin after disease progression on immune checkpoint inhibitor for patients with metastatic urothelial carcinoma — Europe PMC PMID:42539996

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42539996
DOI
10.37349/etat.2026.1002387
License (as archived)
solo-consultazione
Archived
2026-10-17T10:35:08.693Z
SHA-256 of the archived text
16d088f2fb9f011dfad277045b9ce8d88d956de05923fd35a04d57fd8c7d2765
Stable URL of this page
https://metraipolis.com/documento/dc_04ed945176ef

How to cite

Paclitaxel and carboplatin after disease progression on immune checkpoint inhibitor for patients with metastatic urothelial carcinoma — Europe PMC PMID:42539996 — Europe PMC (en), https://europepmc.org/article/MED/42539996 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_04ed945176ef (Metraipolis archive dc_04ed945176ef, sha256 16d088f2fb9f011dfad277045b9ce8d88d956de05923fd35a04d57fd8c7d2765)
BibTeX
@misc{dc04ed945176ef,
  title = {Paclitaxel and carboplatin after disease progression on immune checkpoint inhibitor for patients with metastatic urothelial carcinoma — Europe PMC PMID:42539996},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42539996},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_04ed945176ef; sha256 16d088f2fb9f011dfad277045b9ce8d88d956de05923fd35a04d57fd8c7d2765},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42539996. Agents can read the archived copy with the MCP tool read_document.